Financial results | Navamedic

healthcare professionals

Product areas
Business development
Investors
About

Product areas
Business development
Investors
About

Financial results

Stock exchange news

plus

minus

Offer regarding Sensidose

Navamedic share

plus

minus

Annual General Meeting
Top 20 shareholders

Financial results

plus

minus

Annual reports
Investor Presentations
Prospectus

Financial calendar

Corporate governance

Financial results

2019
2020
2021
2022
2023

Q1

Q1 Presentation 2019

Q2

Q2 & Half Year Presentation 2019
Navamedic ASA - Second quarter 2019 presentation

Q3

Q3 Presentation 2019

Q4

Q4 Presentation 2019

Q1

Webcast Q1
Q1 Presentation 2020

Q2

Webcast Q2
Navamedic Q2 2020 Presentation
Navamedic Q2 and 1H 2020 Report

Q3

Webcast Q3
Navamedic Q3 2020 Presentation

Q4

Webcast Q4
Navamedic Q4 2020 Presentation

Q1

Q1 Webcast
Navamedic Q1 2021 Presentation

Q2

Q2 Webcast
Navamedic ASA Q2 2021 Presentation
Navamedic ASA Q2 and 1H 2021 report

Q3

Q3 Webcast
Navamedic Q3 2021 Presentation

Q4

Q4 Webcast
Navamedic_Q4_2021_Presentation

Q1

Q1 Webcast
Navamedic Q1 2022 Presentation

Q2

Q2 Webcast
Navamedic ASA Q2 2022 Presentation
Navamedic ASA Q2 and 1H 2022 Report

Q3

Q3 Webcast
Navamedic Q3 2022 Presentation

Q4

Q4 Webcast
Navamedic Q4 2022 Presentation

Q1

Q1 Webcast
Navamedic Q1 2023 Presentation

Q2

Q2 Webcast
Navamedic Q2 2023 Presentation
Navamedic Q2 H1 2023 report

Product areas

Consumer health
Specialty pharma
Medical nutrition
Branded generics

Contact us

Do you have any queries or comments about our website, our products or any of our services?

Contact us

Copyright © Navamedic

Conditions of Use
Information about cookies
Privacy policy

Newsletter

.

Newsletter

Sign up for Navamedics newsletter on obesity to get the latest news and research within the obesity area.

Email Address *

First Name *

Last Name *

Language *

By subscribing to our newsletter, you accept our privacy policy.